CRLF2 overexpression in B-ALL patients with an IGH-CRLF2 translocation activates JAK-STAT, PI3K and ERK/MAPK signaling pathways. Although inhibitors of these pathways are available, investigating alternate targets could reduce treatment-associated toxicities.
of CRLF2. The IGH-CRLF2 translocation occurs in precursor cells and is thought to result from aberrant rejoining during V(D)J-recombination 10, 11 . This translocation is most commonly found in adolescents and adult patients and is typically associated with a poor prognoses, while the P2RY8-CRLF2 fusion is found in younger patients 1 .
CRLF2 chromosomal alterations are often accompanied by mutations in JAK1, JAK2 and Ikaros (IKZF1) genes. Several groups have suggested that aberrant CRLF2 signaling cooperates with mutant JAK and IKZF1 activity to promote the development of leukemia 9, 12, 13 .
As a result, the focus has shifted towards the use of signal transduction inhibitors (STIs) to target JAK-STAT, PI3K and MAPK signaling pathways 1 . Although, STIs have shown promise in early clinical trials [14] [15] [16] , broad application of signal transduction inhibitors is challenging due to the interconnected roles of their targets in biological processes (i.e. JAK kinases) including immunity and hematopoiesis 17 . Moreover, it has been shown that mutated JAK2 is required for the initiation of leukemia, but it is not necessary for its maintenance 18 . Therefore, there is a need to more closely investigate the genome-wide impact of the IGH-CRLF2 alteration in B-ALL to aid in the identification of novel therapeutic targets.
To do so, we first sought to identify transcriptional regulators that control differentially expressed genes associated with the IGH-CRLF2 translocation through a comparative analysis of translocated versus non-translocated (Non-T) IGH-CRLF2 B-ALL samples in both patients and cell lines. While robust genome-wide changes in gene expression were separately observed in patients and cell lines, only a small subset of changes were consistent amongst the two groups. Thus, we chose to define the IGH-CRLF2 associated gene set using only patient samples. We constructed a B-ALL transcriptional network to define the interactions between transcription factors (TFs) and the genes they regulate [19] [20] [21] using 529 B-ALL patient samples from the NCI TARGET database. We inferred the targets of TFs linked to the gene set associated with the IGH-CRLF2 cohort using the Inferelator algorithm 22, 23 , along with RNA-seq, ATAC-seq, and TF-motif analysis. The network was then used to predict differential transcription factor activity (TFA) in IGH-CRLF2 versus non-translocated (Non-T) samples. This approach enabled the identification of ten potential regulators of differentially expressed genes (including DNMT1, EGR1, FOXP1, ZBTB7A). The differentially expressed gene targets of these TFs are enriched in anticipated and novel CRLF2-associated pathways. Transcription of several of these gene targets (IL1RAP, LEF1, PPP1R13B, etc.) change across all patients and cell line samples.
It is of note that these genes have been implicated in both Acute myeloid leukemia (AML) 24, 25 and ALL 26, 27 . Thus, it is plausible that the genes along with their regulators could contribute to the maintenance of leukemia and be potential candidates for therapeutic targeting in IGH-CRLF2 B-ALL. The network-based approach we applied has been similarly implemented in several other systems to infer regulatory interactions that have been experimentally validated [28] [29] [30] [31] .
RESULTS:

Genome-wide transcriptional changes in primary IGH-CRLF2 patient samples
Traditional chemotherapy is non-specific and targets rapidly dividing cells. As a result, toxicity results in injury to healthy cells, causing further morbidity and at times, can be doselimiting 32 . To reduce overall toxicity and improve prognosis, most research has been directed towards understanding the underlying molecular pathology of the leukemia. In this study, we focused on identifying pathways associated with the IGH-CRLF2 translocation (Fig. 1a) with the goal of finding new potential therapeutic targets in this subset of B-ALL patients.
Gene expression profiles associated with the IGH-CRLF2 translocation were identified by comparing RNA-sequencing from 17 primary B-ALL patient samples, with the translocation (n=13) with non-translocated (Non-T, n=4) patients. Differential analysis performed using DESeq2 33 uncovered a total of 1,179 de-regulated genes with an adjusted p-value of less than 0.01 and |log2FoldChange| >1 ( Fig. 1b) . Of these 507 genes (~43%) were up-regulated and 669 (~57%) down-regulated in the IGH-CRLF2 translocated patients. To determine whether the gene expression changes were localized to the translocated chromosomes we analyzed the percentage of differentially expressed genes per chromosome. The results clearly demonstrate that expression changes are distributed across all chromosomes and there is no enrichment of deregulated genes on chromosome 14 or the pseudoautosomal region of X/Y ( Supplementary   Fig. 1a ).
To further analyze the changes in gene expression between the IGH-CRLF2 and the Non-T patient samples we performed a principal component analysis. This revealed a clear separation between the two groups of patients ( Supplementary Fig. 1b ). In addition, hierarchical clustering of the 1,179 differentially expressed genes not only separates the IGH-CRLF2 and Non-T samples, but also clearly divides the IGH-CRLF2 patients into two groups, referred to as Group 1 and Group 2 ( Fig. 1c) . These two groups could not be distinguished by the presence or absence of activating mutations in JAK and IKZF1 which were found in most of the translocated cohort: 12/13 and 10/13 IGH-CRLF2 patients, respectively ( Fig. 1c) . As expected the IGH-CRLF2 translocation clearly results in the up-regulation of CRLF2 (log2FoldChange= 5.53) in the translocated versus Non-T control patient samples as shown by RNA-seq tracks on IGV ( Fig. 1d ), suggesting activation of JAK-STAT signaling. Furthermore, SOCS6, a suppressor gene of cytokine signaling 34 , is statistically significantly down-regulated (log2FoldChange= -1.68) in IGH-CRLF2 samples ( Supplementary Fig. 1c ), further supporting the observation that JAK-STAT 1,4 signaling is activated in these samples.
Using the log2 fold changes of the 1,179 differentially expressed genes, ingenuity pathway analysis (IPA) was performed. Positive and negative z-scores indicate pathways that are activated or repressed respectively in the IGH-CRLF2 samples. The IPA analysis ( Supplementary Fig. 1d ) identified 20 significant pathways, the majority of which (19/20) had negative z-scores, indicating that the majority of the pathways are repressed. The PI3K and ERK pathways were included in the repressed cohort which was unexpected as activation of these pathways is normally linked to CRLF2 overexpression 7 , Additionally, the JAK-STAT signaling pathway did not emerge as being statistically enriched according to the gene set we defined, despite the fact that translocated patients have activating mutations in JAK genes. One possible explanation for this outcome is that heterogeneity between patient samples leads to noise in gene expression changes which blurs the analysis. In summary, analysis of RNA-seq data in primary patient samples identifies many significant transcriptional changes associated with the translocated IGH-CRLF2 chromosomal alteration. Furthermore, hierarchical clustering of the patient samples using the differentially expressed gene list, not only clearly distinguishes IGH-CRLF2 patients from Non-T, but also defines two distinct IGH-CRLF2 group of patients. Differential analysis between the two distinct Group 1 and Group 2 patients results in 456 differentially expressed genes. Although pathway analysis results in no significant pathway enrichment we identified six differentially expressed genes involved in p53 signaling, including the proto-oncogene MDM2 and p53 regulator MDM4 that are down-regulated in Group 1 (Fig.   1e ). We postulated there maybe a link between p53 signaling and relapse but were not able to confirm whether p53 signaling in one subtype provides any advantage in this context, as there were 25% (1 of 4) Group 1 patients that relapsed, compared to 33% (3 of 9) of patients in Group 2.
IGH-CRLF2 patient samples have limited changes in chromatin accessibility
To further investigate the impact of the IGH-CRLF2 translocation, we hypothesized IGH-CRLF2 transcriptional changes could be accompanied by changes in chromatin accessibility. To test this hypothesis, we performed ATAC-sequencing and compared chromatin accessibility in IGH-CRLF2 versus Non-T patient samples (18 IGH-CRLF2 and 6 Non-T). These patient numbers are different to the numbers used for RNA-seq analysis as some of the patient samples for RNA-seq did not pass quality control. Differential analysis of all the ATAC-seq peaks identified 162 regions that were more accessible and 126 regions with reduced accessibility in the IGH-CRLF2 translocated condition ( Fig. 2a) . The majority of ATAC-seq peaks were not significantly differential, indicating accessibility is for the most part stable between IGH-CRLF2 and Non-T patient samples. Significant accessibility changes were evenly distributed across promoters, gene bodies, and intergenic regions ( Supplementary Fig. 2b ).
Differential peaks were assigned to promoters (within 3kb of TSS), UTRs, exons and introns of genes ( Fig. 2b) . About 82.6% (238) of differential ATAC-seq peaks were associated with genes (n=224), either on promoters or gene bodies. Of the genes that had at least one differential ATAC-seq peak in the promoter or gene body, 14.2% (32) were significantly differentially expressed in IGH-CRLF2 versus Non-T patient samples. The majority of the differential ATAC-seq peaks that overlap differentially expressed genes were regulated in the same direction, with the exception of 7 ATAC-gene pairs (Fig. 2b) . In the example shown in Fig.   2c , three significantly more accessible peaks were associated with overexpressed DPP4 in IGH-CRLF2 patients. Conversely, the down-regulated PKIA gene was linked to a significant reduction in accessibility ( Supplementary Fig. 2c ). We also observed several instances where a significant change in accessibility was linked to a gene whose expression was not affected by the IGH-CRLF2 translocation (Supplementary Fig. 2d ). Importantly, the majority of transcriptional changes were not associated with significant changes in chromatin accessibility near the promoter or within the gene bodies ( Fig. 2d) , as demonstrated for the RRAS gene and two other examples shown in Fig. 2e, Supplementary Fig. 2e-f . Thus, we conclude that overall, the IGH-CRLF2 translocation leads to limited genome-wide chromatin accessibility changes and accessibility remains stable even at promoter regions of differentially expressed genes. However, we postulated that differences in transcription factor (TF) binding at stable ATAC-seq peaks could influence gene expression changes and turned to patient-derived cell lines as a model to address this question.
Transcriptional changes in patient IGH-CRLF2 derived cell lines are not recapitulated in patient samples
The patient-derived cell lines used in our analysis were MHH-CALL-4 35 (CALL) and MUTZ5 36 Supplementary Fig. 3a) indicates that the majority of the variance (71%) lies between IGH-CRLF2 cell lines and Non-T cell lines, while about 26% of variance separates the two translocated cell lines. Thus the PCA analysis indicates that the IGH-CRLF2 translocation is the major cause of differences between the two conditions, consistent with what was observed in patient samples.
Differential gene expression analysis of CALL versus SMS (3,045 DE genes) and MUTZ
versus SMS (2,702 DE genes) identified thousands of differentially expressed genes ( Fig. 3b) , with roughly equivalent numbers of up and down-regulated genes in each case. The number of overlapping differentially expressed genes (ie those likely to be related to the translocation event) is shown in Fig. 3c . As with the patient samples, the gene expression changes were distributed across all chromosomes ( Supplementary Fig. 3b ). Fig. 3d , the log2 fold change of (CALL/SMS) and (MUTZ/SMS) demonstrated that about 97% of the genes were in convergent orientation (960 up-regulated, 772 down-regulated). However, of the common 1,732 convergent differentially expressed genes in the cell lines, only 221 overlapped with the differentially expressed genes found in translocated versus non-T patient samples ( Fig. 3e) . Furthermore, only 181 out of the 221 genes were in convergent orientation ( Fig. 3f) , indicating that the profile of gene expression changes in cell lines may not be the best representation of what is occurring in patients.
As shown in
Furthermore, no significantly enriched pathways were identified from the overlapping gene set.
To identify the gene list that best separates the translocated class from the nontranslocated class, we performed PCA using the differentially expressed genes from cell lines (Set 1) and patient samples (Set 2). The PCA results associated with the 1,792 differentially expressed genes from Set 1, demonstrate a clear separation between translocated cell lines and non-translocated cell lines. In contrast, the patient samples cluster together and do not separate according to the PC scores calculated using Set 1 genes ( Fig. 3g -upper panel) . In contrast, when the PCA associated with Set 2 was performed (1,176 differentially expressed genes in patients), we found a clear separation between cell lines and patients on the first principal component that separates the IGH-CRLF2 from Non-T condition on the second principal component, indicating that Set 2 genes are more representative of the effect of the translocation in both primary patient samples and cell line samples ( Fig. 3g -lower panel). In summary, we found many significant transcriptional changes in cell lines but only a subset of these were recapitulated in patients. On the other hand, the top 500 patient-associated transcriptional changes can be used to not only distinguish between patients and cell lines (PC1), but also clearly separate the IGH-CRLF2 samples from the Non-T samples (PC2).
Chromatin accessibility changes in IGH-CRLF2 translocated cell lines are more numerous than those in patient samples
Our analyses reveal little compatibility in expression changes between IGH-CRLF2 and
Non-T in cell lines and patient samples. To investigate this further we analyzed chromatin accessibility using ATAC-sequencing. Significant ATAC-seq peaks were called and a reference peakome of 41,111 peaks was created to include all possible ATAC-seq peaks across the three cell lines, CALL, MUTZ, and SMS. DESeq2 analysis on the cell line peakome identified 2,550 altered ATAC-seq peaks between CALL and the SMS control, and 2,718 between MUTZ and the SMS control (Fig. 4a) . The overlap between the two comparisons identified 1,396 differentially accessible ATAC-seq peaks ( Fig. 4b) , of which 99.7 % (1392/1396) were in convergent orientation (Fig. 4c) . This number is incompatible with the total number of differentially accessible ATAC-seq peaks (288) identified in patient samples. However, we postulated that regions that were changing in patients should change similarly in cell lines. To determine this, we ranked all differential ATAC-seq peaks in patient samples ( Fig. 2a ) according to fold change and adjusted p-value, and took the 162 most accessible peaks and 126 least accessible peaks in IGH-CRLF2 patient samples and calculated the ATAC signal of the cell lines at these regions. The limited alterations in accessibility in patients were weakly recapitulated in cell lines as shown in Fig. 4d However, compared to the stability of ATAC-seq peaks in patients, we observed more alterations in acessbility in cell lines. This finding further supports the conclusion that using cell lines as a model to study the IGH-CRLF2 translocation is not ideal. Therefore, all the downstream analysis focused solely on the transcriptional changes identified in patient samples.
Construction of a B-ALL regulatory network using ATAC-motif derived priors
CRLF2 overexpression activates a signaling cascade that involves many TF regulators and gene targets. Although, we identified a subset of gene expression changes that could be important for the pathogenesis of the leukemia, it is not clear how all of these genes are regulated and connected. Here, our aim was to first identify which TFs could potentially be regulating the differentially expressed genes we identified, and second to infer the relationship between these TFs and their target genes. To address this, we performed TF-motif analysis, using FIMO 38 , at ATAC-seq peaks that fall within promoter regions (20kb upstream of TSS) of all genes genome-wide. We used a hyper-geometric test to test for enrichment of TF-motifs at differentially expressed genes, which resulted in 102 unique significant TF motifs enriched at significantly up-and down-regulated genes with four motifs DMRTC2, DUXA, PITX1, and PITX3 were found in both sets (Fig. 5a) . Thus, motif enrichment analysis resulted in a list of 102 unique potential TF regulators that could be important for the regulation of the IGH-CRLF2 associated gene signature.
To better understand the relationship between the candidate TF regulators identified in Recent studies have incorporated prior information of TF target genes from different data types, like ChIP-seq, ATAC-seq, and TF-motif analysis to considerably improve network inference [28] [29] [30] 39 . Here, we focused on combining chromatin accessibility data together with TFmotif analysis of the IGH-CRLF2 cohort to generate priors and infer the B-ALL network (Fig.   5b ). We selected only regulatory interactions of TFs that were significantly enriched at promoters of differentially expressed genes between IGH-CRLF2 and Non-T patient samples (102 TFs -Fig. 5a ). Transcription factor activities estimated using the ATAC-seq motif derived priors and the gene expression matrix obtained from the TARGET database were used for the Inferelator algorithm ( Fig. 5b) . Finally, a B-ALL specific regulatory network involving 102 TFs and 37,086 interactions with combined confidences > 0.5 was inferred. The number of gene targets inferred for each individual TF is shown in Supplementary Fig. 4a , and the number of differentially expressed gene targets in the IGH-CRLF2 cohort are shown in Supplementary   Fig. 4b .
Defining a sub-regulatory network with TFs affected by CRLF2 alteration
Transcriptional regulatory networks shed light on the relationship between transcription factors (TFs) and their gene targets. Here, we constructed a B-ALL specific regulatory network involving 102 TFs that may be important regulators of the IGH-CRLF2 gene signature. To narrow down the list, we created a sub-network and identified TF regulators in the IGH-CRLF2 cohort that were altered either at the mRNA level or the protein activity level. First, we analyzed the expression levels of all genes encoding the 102 TF regulators and identified five TF regulators that were significantly differentially expressed between IGH-CRLF2 and Non-T patients (Supplementary Fig. 4c ). Next, we determined TFs that had differences in their activity in the IGH-CRLF2 cohort. Transcription factor activity (TFA) is commonly estimated from mRNA levels, however since posttranslational modifications can influence TF activity, use of mRNA as a proxy for TFA is not the best approach. If prior knowledge of interactions involving TFs and their target genes is available it can considerably improve TFA estimation and network inference 28, 30 . Thus, to estimate the activities of the 102 TFs identified from motifs of significantly up-and down-regulated genes in the IGH-CRLF2 versus Non-T patients, a normalized gene expression matrix was used. This was combined with priors of TF-gene interactions identified from the inferred B-ALL regulatory network (Fig. 5b) . Sixteen TFs had significant differences in the mean estimated TFA in the IGH-CRLF2 cohort (Supplementary Fig. 4b ) and five had significantly altered levels of expression giving a total of twenty significant TF regulators (ZNF713 was identified in both analyses (Fig. 5c) . TFs with no significant differences in mean TFA are shown in Supplementary Fig. 5a . We note that many TFs with significantly altered activity are implicated in cancer. For instance, FOXP1, a member of the forkhead family of transcription factors is known to play important roles in B-cell development and lymphoid malignancies 40 and could therefore potentially contribute to tumorigenesis in B-ALL patients with the IGH-CRLF2 alteration.
We previously suggested that heterogeneity between patients could lead to noise in the IGH-CRLF2 gene signature. To filter gene expression changes we focused on inferred target genes of TFs that are affected by CRLF2 overexpression, either at the transcriptional level or TF activity level. The 6,545 regulatory interactions in Fig. 5c describe the relationship between significantly differential TFs and their gene targets. Of these, 387 interactions are regulatory interactions involving differentially expressed genes (329 out of a total of 1177 unique genes -28%) in the IGH-CRLF2 versus Non-T patient cohort (Fig. 6a,b) . We define the filtered list of 329 differentially expressed genes and their twenty TF regulators as the CRLF2 specific subnetwork (Fig. 6c) . The number of differentially expressed gene targets for each TF regulator is shown in Supplementary Fig. 6a . As seen in Supplementary Fig. 6b , several differentially expressed gene targets are regulated by more than one TF.
Differentially expressed gene targets of TFs with predicted altered activity are enriched in expected and novel CRLF2-associated pathways
We performed pathway analysis focusing on the differentially expressed gene targets in the CRLF2-altered sub-network ( Fig. 7a ) and identified 21 enriched pathways including the anticipated activation of canonical JAK-STAT, PI3K, and ERK pathways. Thus, in contrast to our initial analysis which focused on all differentially expressed genes in the IGH-CRLF2 translocated versus Non-T patient samples, we were able to identify known CRLF2-associated pathways including the JAK-STAT signaling pathway. These findings validate the approach taken in order to identify a more CRLF2-relevant differentially expressed gene list. In Fig. 7a , differentially regulated genes (33) are labeled and connected with the appropriate pathway. For example, PI3K up-regulation of signaling is linked to the differential expression of SOCS6, RALB, RRAS, and PTPN6. Additionally, the FLT3 signaling 41, 42 pathway, which is known to be associated with CRLF2 overexpression, is identified as being upregulated.
The other pathways identified by our analyses could also be playing an important role in CRLF2-overexpressing B-ALL. As such, we wanted to define a handful of interesting genes that could have the highest potential as therapeutic targets. For this, we compared all 33 differentially expressed genes in the patient samples and in each pairwise cell line comparison (CALL versus SMS, and MUTZ versus SMS). Although, we previously found that patient-derived transcriptional changes and cell line-derived transcriptional changes do not strongly overlap, there are some patient-derived transcriptional changes that are recapitulated in the cell lines.
Thus, we compared log2 fold changes and significance of the 33 differentially expressed genes across all patient and cell line comparisons ( Fig. 7b) and identified six common genes.
Upregulation of IL1RAP, LEF1, CD79B, CTGF, and repression of PPM1H, PPP1R13B was robust across all IGH-CRLF2 patient and cell lines. Previous studies [24] [25] [26] [27] 43, 44 implicate the majority of these genes in hematologic malignancies but their affect on IGH-CRLF2 B-ALL is not known. Therefore, analysis of the changes in TF activity and gene target mRNA level in the CRLF2 affected sub-network identified a list of genes that are strong candidates for targeted therapies in IGH-CRLF2 translocated leukemia.
Discussion
Patients with B-ALL who carry the IGH-CRLF2 translocation are at increased risk for refractory disease and relapse. This alteration leads to CRLF2 overexpression and activation of JAK-STAT and other associated pathways 1 . Available treatments include non-specific cytotoxic chemotherapies which are often effective but responsible for many of the toxicities seen in these patients. The addition of Tyrosine-Kinase Inhibitors and JAK inhibitors in the treatment of leukemias has allowed for targeted treatments with fewer toxicities, however, alternate pathwayspecific therapies are needed to further tailor treatment. To better study the impact of the IGH-CRLF2 translocation, we analyzed RNA-seq from rearranged IGH-CRLF2 and Non-T B-ALL patient samples and identified hundreds of differentially expressed genes, but were unable to link these changes to the expected pathway alterations associated with the IGH-CRLF2 translocation. We subsequently analyzed ATAC-seq data to evaluate the effect of this genetic alternation on DNA accessibility. We found accessibility to be mostly stable near the promoters of genes with altered gene expression and conclude that chromatin accessibility is not driving changes in the transcriptional landscape. Instead, we inferred binding of specific proteins at accessible sites at differentially expressed gene promoters that influence transcription.
Leveraging hundreds of available B-ALL RNA-seq samples from the TARGET database along with prior knowledge of TF-motifs at accessible promoters, we inferred a global B-ALL network.
Deeper investigation of the TF regulators and their targets in this network identified a candidate list of potential therapeutic targets. 24 . IL1RAP plays an important role in potentiating AML cells, and there is strong evidence for its therapeutic effects in AML. However, its function in B-ALL is not known.
Other candidates, LEF1 and PPP1R13B have also been implicated in cancer. Lymphoid enhancer-binding factor 1, LEF1, is a transcription factor that acts downstream of the Wnt/βcatenin signaling pathway. This TF can independently regulate gene expression and is necessary for stem cell maintenance and organ development 26 . Disrupted LEF1 is associated with cancer progression and proliferation of cells in ALL, chronic lymphocytic leukemia (CLL), Burkitt lymphoma (BL), and colorectal cancer (CRC) 26 . In particular, one study clearly shows high expression of LEF1 associated with shorter relapse-free survival (RFS) in B-ALL 27 . Overall, this gene is considered a biomarker for patient prognosis in many hematological malignancies.
Though, we now provide evidence suggesting that it has a specific role in leukemogeneis in translocated IGH-CRLF2 patients. Additionally, PPP1R13B, another candidate target, encodes a member of the apoptosis stimulating p53 family of proteins (ASPP), this gene is known to be repressed in ALL and its reduced expression is due to hypermethylation of the PPP1R13B gene promoter 43, 44 .
DNA methylation is associated with transcriptional repression and is maintained by the correlate with reduced gene expression including genes involved in cytokine-receptor interactions 45 . We hypothesize that methylation could be playing a role in this context.
Overall, we have investigated the transcriptional impact of CRLF2 overexpression in a high-risk subset of B-ALL patients. Using an integrative approach, we derived regulatory interactions that have identified strong candidates for targeted therapies in B-ALL patients with an IGH-CRLF2 translocation or other leukemias. IL1RAP, LEF1, and PPP1R13B are amongst the most interesting candidates as there is strong evidence for their role in hematological malignancies. The strategy we have used here can further be adapted to elucidate important regulators responsible for additional subsets of B-ALL and other challenging pediatric malignancies. 
Methods
All methods are available in supplemental note section of supplemental information
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